The aim of this study was to investigate the potential role of soluble Human Leukocyte Antigen-G (sHLA-G) molecules as biomarkers predicting outcome in acute ischemic stroke (AIS). Serum levels of total sHLA-G (sHLA-G1/HLA-G5) and its soluble isoforms sHLA-G1 and HLA-G5/G6 were measured by enzyme-linked immunosorbent assay (ELISA) in 92 AIS patients and healthy donors (HD). Incidence of hemorrhagic transformation (HT), size of final infarct volume (FIV) and clinical outcome at 3 months were recorded in AIS patients. Detectable serum levels of sHLA-G1/HLA-G5, HLA-G5/G6 and sHLA-G1 were present in a small proportion of AIS patients (26.1%, 17.4% and 16.3%, respectively) and HD (12.5%, 10.7% and 10.7%, respectively) and were more elevated in AIS patients without HT than in those with HT (p < 0.01; p < 0.05; p < 0.01, respectively). HT was less frequent (p < 0.01) in AIS patients with measurable serum concentrations of sHLA-G1/HLA-G5 and HLA-G5/G6. Serum levels of sHLA-G1/HLA-G5 and sHLA-G1 were inversely correlated to FIV (p < 0.02), whereas good outcome was more common (p < 0.01) in AIS patients with detectable serum concentrations of sHLA-G1/HLA-G5. Taken together, these findings suggest that total sHLA-G could exert a protective effect in a subset of AIS patients, irrespective of its soluble isoforms sHLA-G1 and HLA-G5/G6, and indicate that the prognostic value of serum levels of sHLA-G remains to be established.

中文翻译：

---

急性缺血性卒中患者血清可溶性HLA-G水平的检测：一项先导研究。

这项研究的目的是调查可溶性人类白细胞抗原-G（sHLA-G）分子作为预测急性缺血性卒中（AIS）结局的生物标志物的潜在作用。通过酶联免疫吸附法（ELISA）测定了92例AIS患者和健康供体（HD）的总sHLA-G（sHLA-G1 / HLA-G5）及其可溶性亚型sHLA-G1和HLA-G5 / G6的血清水平。在AIS患者中记录了3个月时的出血转化（HT），最终梗死体积（FIV）大小和临床结局的发生率。少数AIS患者（分别为26.1％，17.4％和16.3％）和HD（12.5％，10.7％）中存在可检测的sHLA-G1 / HLA-G5，HLA-G5 / G6和sHLA-G1血清水平分别为10.7％和10.7％），并且没有HT的AIS患者比有HT的患者更高（分别为p <0.01; p <0.05; p <0.01）。血清中sHLA-G1 / HLA-G5和HLA-G5 / G6浓度可测量的AIS患者HT发生率较低（p <0.01）。血清sHLA-G1 / HLA-G5和sHLA-G1与FIV呈负相关（p <0.02），而在AIS患者中血清sHLA-G1 / HLA-可检测到的良好结局更常见（p <0.01）。 G5。综上所述，这些发现表明，总sHLA-G可以对一部分AIS患者发挥保护作用，而不论其可溶性亚型sHLA-G1和HLA-G5 / G6为何，并表明血清sHLA-G的预后价值G有待建立。01）在AIS患者中可检测到sHLA-G1 / HLA-G5的血清浓度。综上所述，这些发现表明，总sHLA-G可以对一部分AIS患者发挥保护作用，而不论其可溶性亚型sHLA-G1和HLA-G5 / G6为何，并表明血清sHLA-G的预后价值G有待建立。01）在AIS患者中可检测到sHLA-G1 / HLA-G5的血清浓度。综上所述，这些发现表明，总sHLA-G可以对一部分AIS患者发挥保护作用，而不论其可溶性亚型sHLA-G1和HLA-G5 / G6为何，并表明血清sHLA-G的预后价值G有待建立。